# Vantive Health LLC clinical trials: 55 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 55 trials with Vantive Health LLC as lead sponsor, 3 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Vantive Health LLC: 55 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/vantive-health-llc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 55
- Recruiting or not yet: 3
- Read on: November 19, 2026

## Trials

The 25 newest of 55, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 24, 2026 | NCT07781124 | Clinical Effectiveness and Resource Use in End-Stage Renal Disease Patients: Remote Patient Monitoring Across Dialysis Modalities | Vantive Health LLC | Observational | Recruiting | End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD) | 750 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07781124) |
| January 8, 2026 | NCT07326215 | A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+ | Vantive Health LLC | Not applicable | Recruiting | Acute Respiratory Distress Syndrome, Acute Kidney Injury | 99 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07326215) |
| May 21, 2025 | NCT06983509 | Registry of Pre-mixed Solutions in Critically Ill Patients on the Continuous Renal Replacement Therapy | Vantive Health LLC | Observational | Completed | Renal Insufficiency | 228 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06983509) |
| October 9, 2024 | NCT06633029 | Retrospective Analysis of Prismaflex HF20 Set Versus ppCRRT Registry | Vantive Health LLC | Observational | Completed | Acute Renal Failure (ARF), Acute Kidney Injury (AKI), Fluid Overload in Dialysis Patients | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06633029) |
| July 9, 2024 | NCT06492031 | Observational Study of the Use of Extraneal in Peritoneal Dialysis in Patients | Vantive Health LLC | Observational | Completed | Chronic Renal Failure | 439 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06492031) |
| June 5, 2023 | NCT05888376 | A Post-Market Clinical Performance and Safety Evaluation of GamCath HighFlow Dolphin Protect Catheter | Vantive Health LLC | Observational | Completed | AKI - Acute Kidney Injury, Acute Renal Failure, CKD, ESRD | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05888376) |
| June 1, 2022 | NCT05399537 | Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT | Vantive Health LLC | Phase 3 | Recruiting | Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT), Acute Kidney Injury (AKI) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05399537) |
| April 4, 2022 | NCT05309291 | Theranova Randomized, Controlled, Trial (RCT) in China | Vantive Health LLC | Not applicable | Completed | Chronic Kidney Failure, Acute Kidney Failure | 323 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05309291) |
| November 5, 2020 | NCT04617093 | Post-Market Study of Low-flow ECCO2R Using PrismaLung+ | Vantive Health LLC | Not applicable | Completed | Mild to Moderate Acute Respiratory Distress Syndrome | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04617093) |
| March 1, 2019 | NCT03859830 | Clinical Observation of the Performance of Artis Dialysis System, ArtiSet PrePost and Ultra HDF Line in Treatments of Patients With... | Vantive Health LLC | Not applicable | Completed | End-Stage Renal Disease | 276 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03859830) |
| January 23, 2019 | NCT03812679 | Performance Evaluation of the AMIA APD Solution Generation System in Patients End Stage Renal Disease (ESRD) | Vantive Health LLC | Not applicable | Terminated | End Stage Renal Disease (ESRD) | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03812679) |
| June 6, 2018 | NCT03547336 | Study in End Stage Renal Disease (ESRD) Patients on Hemodialysis Comparing the Theranova Dialyzer to Hemodiafiltration | Vantive Health LLC | Not applicable | Completed | End Stage Renal Disease | 212 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03547336) |
| June 6, 2018 | NCT03547323 | Study in End Stage Renal Disease (ESRD) Patients on Hemodialysis to Determine Non-inferiority of the Theranova Dialyzer Compared to the... | Vantive Health LLC | Not applicable | Completed | End Stage Renal Disease | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03547323) |
| April 17, 2018 | NCT03499691 | Exploratory Study to Explore the Safety and Efficacy of the HDx Therapy Using Theranova 500 Dialyzer in Comparison to Hemodiafiltration | Vantive Health LLC | Not applicable | Completed | End Stage Renal Disease | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03499691) |
| August 22, 2017 | NCT03257410 | Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients | Vantive Health LLC | Not applicable | Completed | End Stage Renal Disease | 172 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03257410) |
| August 9, 2016 | NCT02860130 | Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT) | Vantive Health LLC | Phase 3 | Terminated | Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT), Acute Kidney Injury | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02860130) |
| June 10, 2016 | NCT02795286 | Automated Setting of Individualized Sodium Technology | Vantive Health LLC | Not applicable | Completed | End Stage Renal Disease (ESRD) | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02795286) |
| September 28, 2015 | NCT02561247 | Prismaflex HF20 Set and Prismaflex® System 7.10/7.20 for Acute Continuous Renal Replacement Therapy (CRRT) in Children | Vantive Health LLC | Not applicable | Terminated | Acute Kidney Injury in Pediatric Patients | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02561247) |
| March 4, 2015 | NCT02378350 | Quality of Life on Peritoneal Dialysis Versus Hemodialysis in China | Vantive Health LLC | Phase 4 | Completed | End Stage Renal Disease | 668 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02378350) |
| March 3, 2015 | NCT02377622 | Clinical Performance Comparison of 2 THERANOVA 400 Dialyzer Prototypes in HD With High-Flux Dialyzers in HD and hv HDF Mode | Vantive Health LLC | Not applicable | Completed | End Stage Renal Disease | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02377622) |
| March 3, 2015 | NCT02377570 | Comparison of the Clinical Performance of 3 THERANOVA 400 Dialyzer Prototypes With a High-Flux Dialyzer in Hemodialysis Mode | Vantive Health LLC | Not applicable | Completed | End Stage Renal Disease | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02377570) |
| March 12, 2014 | NCT02084381 | PERCI- Medium Cut Off (MCO) | Vantive Health LLC | Not applicable | Completed | Chronic Kidney Failure, Chronic Inflammation | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02084381) |
| February 5, 2013 | NCT01783626 | Evaluation of Evodial Hemodialyzer Selectivity Modifications (Evodial +) | Vantive Health LLC | Not applicable | Completed | End Stage Renal Disease (ESRD) | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01783626) |
| November 7, 2012 | NCT01722695 | Performance Comparison of Revaclear With Larger Dialyzer | Vantive Health LLC | Not applicable | Completed | Renal Failure Chronic Requiring Hemodialysis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01722695) |
| April 23, 2012 | NCT01582893 | Permeability Enhancement to Reduce Chronic Inflammation | Vantive Health LLC | Not applicable | Completed | End Stage Renal Disease, Inflammation | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01582893) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 2 | 1 |
| Phase 3 | 5 |
| Phase 4 | 4 |
| Not applicable | 38 |
| Observational | 7 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 42 |
| Terminated | 7 |
| Withdrawn | 3 |
| Recruiting | 3 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Kidney Failure, Chronic | 30 |
| Acute Kidney Injury | 9 |
| Renal Insufficiency, Chronic | 6 |
| Renal Insufficiency | 4 |
| Diabetes Mellitus | 3 |
| Systemic Inflammatory Response Syndrome | 2 |
| Liver Failure | 2 |
| Sepsis | 1 |
| Rhabdomyolysis | 1 |
| Heart Failure | 1 |
| Inflammation | 1 |
| Hypertriglyceridemia | 1 |
| Hepatic Encephalopathy | 1 |
| Hepatitis, Chronic | 1 |
| Liver Cirrhosis | 1 |
| End Stage Liver Disease | 1 |
| Fibrosis | 1 |
| Cardiovascular Diseases | 1 |
| Respiratory Distress Syndrome | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Filipino restaurants in the United States](https://specstream.ai/data/businesses/filipino-restaurants/united-states)
- [Housing or property companies in the United States](https://specstream.ai/data/businesses/housing-or-property-companies/united-states)
- [Manufacturing consultants in the United States](https://specstream.ai/data/businesses/manufacturing-consultants/united-states)
- [Paving contractors in the United States](https://specstream.ai/data/businesses/paving-contractors/united-states)
- [Remodeling contractors in the United States](https://specstream.ai/data/businesses/remodeling-contractors/united-states)
- [Tea wholesalers in the United States](https://specstream.ai/data/businesses/tea-wholesalers/united-states)
